Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Appendix A Supplementary data

    2020-08-07


    Appendix A. Supplementary data
    NMR, IR and UVevis spectra of new compounds 3 and 4; sta-bility studies of AUY922 (NVP-AUY922) Titanofin (4) by NMR and UVevis spectroscopy; crystallographic data for compound 3 (fin); com-plete cytotoxicity and viability profile for bimetallic Titanocref (2), Titanofin (4) and for monometalic cref (1), fin (3) and Auranofin; selected targets found from the Proteome Profiler Human Protease Array assay for compounds 1e4 and Auranofin.
    References
    P. Le Gendre, O. Zava, F. Edafe, et al., Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties, J. Med. Chem. 53 (2010) 6923e6933.
    M. Groessl, O. Zava, H. Amrouche, P.D. Harvey, et al., Multinuclear cytotoxic metallodrugs: physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes, Inorg. Chem. 50 (19) (2011) 9472e9480.
    J. Gut, C.E.J. van Rensburg, P.J. Rosenthal, et al., Platinum(II) and gold(I) complexes based on 1,10-Bis(diphenylphosphino)metallocene derivatives: synthesis, characterization and biological activity of the gold complexes,
    propargylthiopyridine phosphane derivatives as anticancer agents: charac-terization and antitumor activity, Organometallics 32 (2013) 3710e3720. [9] E. Barreiro, J.S. Casas, M.D. Couce, A. Sanchez, J. Sordo, E.M. Vazquez-Lopez, Heteronuclear gold(I)-silver(I) sulfanylcarboxylates: synthesis, structure and cytotoxic activity against cancer cell lines, J. Inorg. Biochem. 131 (2014) 68e75.
    [12] Y. Zaidi, F. Arjmand, N. Zaidi, J.A. Usmani, H. Zubair, K. Akhtar, M. Hossain, G.G.H.A. Shadab, A comprehensive biological insight of trinuclear copper(II)e tin(IV) chemotherapeutic anticancer drug entity: in vitro cytotoxicity and in vivo systemic toxicity studies, Metall 6 (2014) 1469e1479. [13] P. Govender, H. Lemmerhirt, A.T. Huttonm, B. Therrien, P.J. Bednarski, G.S. Smith, First-and second-generation heterometallic dendrimers containing ferrocenyl-ruthenium(II)-Arene Motifs: synthesis, structure, electrochemistry, and preliminary cell proliferation studies, Organometallics 33 (2014) 5535e5545.
    A. Valentin, C. Hemmert, H. Gornitzka, Synthesis, structures, and biological studies of heterobimetallic Au(I)-Ru(II) complexes involving N-heterocyclic carbene-based Multidentate ligands, Organometallics 34 (2015) 1046e1055.
    A. Antinolo,~ J.M. Padron, G.B. Plata, I. Cuadrado, Catalytically generated ferrocene-containing guanidines as efficient precursors for new redox-active heterometallic platinum(II) complexes with anticancer activity, Organome-tallics 34 (2015) 5407e5417.
    [17] A. Nithyakumar, V. Alexander, Synthesis, relaxivity, and in vitro fluorescence imaging studies of a novel def heterometallic trinuclear complex as a po-tential bimodal imaging probe for MRI and optical imaging, Dalton Trans. 44 (2015) 17800e17809.
    A. Varela-Ramírez, R.J. Aguilera, M. Contel, Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu 2 and TiM (M ¼ Pd, Pt) com-pounds. Studies of their interactions with DNA, Inorg. Chem. 50 (2011) 11099e11110.
    [25] J. Fernandez-Gallardo, B.T. Elie, F.J. Sulzmaier, M. Sanaú, J.W. Ramos, M. Contel, Organometallic titanocene-gold compounds as potential chemotherapeutics in renal cancer. Study of their protein kinase inhibitory properties, Organo-metallics 33 (2014) 6669e6681.
    O. Navarro, M. Contel, Titanocene-gold complexes containing N-heterocyclic carbene ligands inhibit growth of prostate, renal, and colon cancers in vitro, Organometallics 35 (2016) 1218e1227.
    L. Messori, Design, synthesis and characterisation of new chimeric ruth-enium(II)egold(I) complexes as improved cytotoxic agents, Dalton Trans. 44 (2015) 11067e11076. [29] J. Fernandez-Gallardo, B.T. Elie, M. Sanaú, M. Contel, Versatile synthesis of cationic N-heterocyclic carbeneegold(I) complexes containing a second ancillary ligand. Design of heterobimetallic rutheniumegold anticancer agents, Chem. Commun. 52 (2016) 3155e3158. [30] B.T. Elie, Y. Pechenyy, F. Uddin, M. Contel, A heterometallic ruthenium-gold  complex displays antiproliferative, antimigratory and antiangiogenic prop-erties and inhibits metastasis and angiogenesis-associated proteases in renal cancer, J. Biol. Inorg. Chem. 23 (2018) 399e411.
    [31] B. Benoît, A. Casini, A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds, Dalton Trans. 43 (2014) 4209e4219 (and refs. therein).
    [35] C. Roder, M. Thomson, Auranofin: repurposing an old drug for a golden new age, Drugs R 15 (2015) 13e20, and refs. therein.